Evidence map›Paper›PMID 25295525›Full record

ArticlePloS one2014

Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling.

Sangkyun Lee, Jörg Rahnenführer, Michel Lang, Katleen De Preter, Pieter Mestdagh, Jan Koster, Rogier Versteeg, Raymond L Stallings, Luigi Varesio, Shahab Asgharzadeh and 5 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. High Dimensional Variable Selection with Error Control.BioMed research international · 2016
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sangkyun LeeDepartment of Computer Sciences, TU Dortmund University, Dortmund, Germany.
Jörg RahnenführerDepartment of Statistics, TU Dortmund University, Dortmund, Germany.
Michel LangDepartment of Statistics, TU Dortmund University, Dortmund, Germany.
Katleen De PreterCenter for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Pieter MestdaghCenter for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Jan KosterDepartment of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.
Rogier VersteegDepartment of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.
Raymond L StallingsCancer Genetics, Royal College of Surgeons, Dublin, Ireland.
Luigi VaresioLaboratory of Molecular Biology, Giannina Gaslini Institute, Genova, Italy.
Shahab AsgharzadehHematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California, United States of America.
Johannes H SchulteDepartment of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany; Centre for Medical Biotechnology, University Duisburg-Essen, Essen, Germany; Translational Neuro-Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kathrin FielitzDepartment of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany.
Melanie SchwermerDepartment of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany.
Katharina MorikDepartment of Computer Sciences, TU Dortmund University, Dortmund, Germany.
Alexander SchrammDepartment of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying relevant signatures for clinical patient outcome is a fundamental task in high-throughput studies. Signatures, composed of features such as mRNAs, miRNAs, SNPs or other molecular variables, are often non-overlapping, even though they have been identified from similar experiments considering samples with the same type of disease. The lack of a consensus is mostly due to the fact that sample sizes are far smaller than the numbers of candidate features to be considered, and therefore signature selection suffers from large variation. We propose a robust signature selection method that enhances the selection stability of penalized regression algorithms for predicting survival risk. Our method is based on an aggregation of multiple, possibly unstable, signatures obtained with the preconditioned lasso algorithm applied to random (internal) subsamples of a given cohort data, where the aggregated signature is shrunken by a simple thresholding strategy. The resulting method, RS-PL, is conceptually simple and easy to apply, relying on parameters automatically tuned by cross validation. Robust signature selection using RS-PL operates within an (external) subsampling framework to estimate the selection probabilities of features in multiple trials of RS-PL. These probabilities are used for identifying reliable features to be included in a signature. Our method was evaluated on microarray data sets from neuroblastoma, lung adenocarcinoma, and breast cancer patients, extracting robust and relevant signatures for predicting survival risk. Signatures obtained by our method achieved high prediction performance and robustness, consistently over the three data sets. Genes with high selection probability in our robust signatures have been reported as cancer-relevant. The ordering of predictor coefficients associated with signatures was well-preserved across multiple trials of RS-PL, demonstrating the capability of our method for identifying a transferable consensus signature. The software is available as an R package rsig at CRAN (http://cran.r-project.org).

Indexed as

AlgorithmsBreast NeoplasmsHumansModels, TheoreticalNeoplasmsNeuroblastomaProportional Hazards Models

Identifiers

PMID25295525
PMCPMC4190101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.